Search alternatives:
"significant based decrease" » "significant cause decrease" (Expand Search), "significant barrier decrease" (Expand Search), "significant burden decrease" (Expand Search), "significant caused decreased" (Expand Search), "significant marked decrease" (Expand Search), "significant based defense" (Expand Search)
"significant increase release" » "significant increased release" (Expand Search), "significant increased reliance" (Expand Search), "significant increase cellarea" (Expand Search)
"significant based decrease" » "significant cause decrease" (Expand Search), "significant barrier decrease" (Expand Search), "significant burden decrease" (Expand Search), "significant caused decreased" (Expand Search), "significant marked decrease" (Expand Search), "significant based defense" (Expand Search)
"significant increase release" » "significant increased release" (Expand Search), "significant increased reliance" (Expand Search), "significant increase cellarea" (Expand Search)
-
1
Image_1_In vitro evaluation of iron oxide nanoparticle-induced thromboinflammatory response using a combined human whole blood and endothelial cell model.pdf
Published 2023“…Furthermore, IONPs mediated a strong thromboinflammatory response, as seen by the significantly increased release of 21 of the 27 analyzed cytokines (p<0.05). …”
-
2
Image_2_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.tif
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”
-
3
Image_4_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.tif
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”
-
4
Image_1_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.tif
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”
-
5
Table_1_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.docx
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”
-
6
Image_3_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.tif
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”
-
7
Table_2_IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.docx
Published 2022“…Nivolumab significantly increased release of MIP1-α, IL-6, and IL-8 from NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, respectively.…”